[1]于宏,曹治宸,耿建英,等.干扰素α治疗慢性乙型肝炎患者肝纤维化的实验研究[J].南方医科大学学报,2005,(11):1409-1412.
 YU Hong,CAO Zhi-chen,GENG Jian-ying,et al.Effect of interferon alpha on liver fibrosis in patients with chronic hepatitis B[J].Journal of Southern Medical University,2005,(11):1409-1412.
点击复制

干扰素α治疗慢性乙型肝炎患者肝纤维化的实验研究()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2005年11期
页码:
1409-1412
栏目:
出版日期:
2005-11-01

文章信息/Info

Title:
Effect of interferon alpha on liver fibrosis in patients with chronic hepatitis B
作者:
于宏 曹治宸 耿建英 贺占国 王政民 孙小云 王中华
中国人民解放军白求恩国际和平医院肝病科, 河北, 石家庄, 050082
Author(s):
YU Hong CAO Zhi-chen GENG Jian-ying HE Zhan-guo WANG Zheng-min SUN Xiao-yun WANG Zhong-hua
Department of Hepatopathy, Bethune International Peace Hospital of PLA, Shijiazhuang 050082, China
关键词:
乙型肝炎干扰素α肝纤维化细胞凋亡Fas基因TGF-β1基因
Keywords:
chronic hepatitis Binterferon alphaapoptosis hepatocyteliver fibrosisFas geneTGFβ1 gene
分类号:
R512.62
摘要:
目的 观察干扰素α对慢性乙型肝炎(乙肝)患者肝组织纤维化程度的影响。方法 选取病理诊断为S3~S4期的16例乙肝患者,干扰素治疗期前后3次进行肝组织炎症程度及纤维化程度病理分析,免疫组化检测肝组织TGF-β1蛋白、Fas及HBcAg抗原,TUNEL方法观察肝细胞凋亡情况。同期检测血清肝纤维化指标及肝功能。结果 在S3~S4期,患者Fas、TGF-β1显著表达,肝细胞的DNA损伤严重。干扰素α治疗3个月后Fas抗原、TGF-β1表达程度显著下降(P<0.05);细胞凋亡程度减轻(P<0.05);肝组织HBcAg表达程度无显著改变;连续6~9个月治疗后,肝组织炎症及纤维化程度逐渐改善(P<0.05),血清肝纤维化指标及肝功能水平与治疗前差异显著。结论 干扰素α能显著改善S3~S4期患者肝细胞凋亡和肝组织纤维化程度,但需持续治疗。
Abstract:
Objective To observe the histological changes in the fibrotic and inflammatory tissues in response to interferon alpha treatment in patients with chronic viral hepatitis B. Methods Sixteen patients with chronic viral hepatitis B in S3-S4 stages established by pathological examination were treated with interferon alpha for 6-9 months, and the degree of liver fibrosis and inflammation were examined 3 times during the treatment. The expression of Fas, transforming growth factor β1 (TGFβ1) and HBcAg in the liver tissues were detected by immunohistochemistry, and DNA fragmentation was examined by TUNEL assay. The levels of the serum markers for liver fibrosis and liver function were also measured. Results Patients with liver fibrosis in S3-S4 stages had high pathological expression of Fas and TGFβ1 with severe DNA damage in the liver tissues. After 3 months of interferon therapy, the expression of Fas and TGFβ1 were lowered (P<0.05), and further treatment till 3-9 months resulted in gradual decrease in the degree of hepatic fibrosis and cell apoptosis (P<0.05), with improved serum liver fibrosis indices and liver function. Conclusion Interferon alpha may alleviate liver fibrosis and suppress cell apoptosis in patients in S3-S4 stages after a 6- to 9-month continuous treatment.

参考文献/References:

[1] 张定国 陈颖伟.肝纤维化研究现状及展望[J].上海第二医科大学学报(Acta Univ Med Sec Shanghai),2005,(1):101-2.
[2] Payatheodoridis GV, Petraki K, Cholongitas E, et al. Impact of interferon alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatis B[J]. J Viral Hepat, 2005, 12(2):199-206.
[3] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志(Chin J Infect Dis),2001,19(1):56-62.
[4] 秦波,张定风,马英,等.乙型肝炎患者肝组织Fas/FasL表达及其在肝细胞凋亡中的作用[J].中华肝脏病杂志(Chin J Hepatic),2001(6):337-40.
[5] 张敏,张玲霞,龙建银,等.慢性病毒性肝炎患者肝组织转化生长因子β1及其mRNA的分布的研究[J].中华肝脏病杂志(Chin J Hepatic),1999,(4):193-4.
[6] 沈秀华.凋亡和肝细胞[J].国外医学·生理病理科学与临床分册,2002,(4):348-9.
[7] Oberhammer FA, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and regressing liver transforming growth factor β[J]. Proc Natl Acad Sci USA., 1992, 89: 5408-12.
[8] 李兵顺,阎文昭,刘金星,等.肝组织与血清转化生长因子β1表达水平与病毒性肝炎患者肝纤维化的关系[J].中华肝脏病杂志(Chin J Hepatic),2004,(5):271-3.
[9] 薛军.Fas系统介导的细胞凋亡与肝纤维化[J].国外医学·流行病学传染病学分册,2003,(1):88-9.
[10] Smolarek C, Strand S, Krammer PH, et al. The APO-1/Fas system is involved in bile-acid induced apoptosis in human hepatocytes[J].Hepatology, 1996, 24: 956-9.
[11] 朱幼芙,骆抗先,何海棠,等.慢性乙型肝炎感细胞Fas表达和凋亡[J].中华肝脏病杂志(Chin J Hepatic),1997,(1):86-7.

相似文献/References:

[1]刘刚,卢光琇. 湖南汉族人群CTLA4 基因+49G/A 多态性与乙肝感染和乙肝源性肝癌相关性的初步研究[J].南方医科大学学报,2010,(08):1838.
 LIU Gang,LU Guang-xiu.Association of CTLA4 gene +49G/A polymorphism with HBV infection and HBV-relatedhepatocellular carcinoma in Hunan Han population[J].Journal of Southern Medical University,2010,(11):1838.
[2]赵金红,王健,江水清,等.慢性乙型肝炎患者CXC趋化因子Mig的表达[J].南方医科大学学报,2006,(11):1589.
 ZHNA Jin-hong,WANG Jian,JIANG Shui-qing,et al.Expression of chemokine monokine induced by interferon-γ in patients with chronic hepatitis B[J].Journal of Southern Medical University,2006,(11):1589.
[3]李梵,闫涛,李克,等.血浆游离DNA用于判断乙型肝炎相关慢加急性肝衰竭的预后—先锋试验结果[J].南方医科大学学报,2014,(02):147.
[4]刘颖,樊蓉,陈简,等.慢性乙型肝炎病毒感染相关肝硬化患者的肾功能及危险因素分析[J].南方医科大学学报,2014,(04):472.
[5]王欣欣,袁国盛,赖静兰,等.HBeAg阳性慢性乙型肝炎患者干扰素治疗24周应答不佳时的治疗方案[J].南方医科大学学报,2015,(06):807.
[6]杨年欢,袁国盛,周宇辰,等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效[J].南方医科大学学报,2016,(06):775.
[7]诸聪妍,卢观婷,祁婷婷,等.乙型肝炎相关慢加急性肝衰竭患者的长期预后及生存质量[J].南方医科大学学报,2018,(06):736.

备注/Memo

备注/Memo:
收稿日期:2005-9-3。
基金项目:白求恩和平医院科研基金资助课题(008号)
作者简介:于宏(1962-),女,硕士,副主任医师,电话:0311-87978435,E-mail:yuhong7@163.com
更新日期/Last Update: 1900-01-01